# Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

> **NCT01221753** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 7 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Human Papilloma Virus

## Interventions

- **DRUG:** docetaxel
- **DRUG:** cisplatin
- **DRUG:** 5-FU
- **RADIATION:** IMRT
- **DRUG:** cetuximab
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT01221753
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2012-07
- **Final completion:** 2017-07
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Due to slow accrual
- **Last updated:** 2017-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01221753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01221753, "Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT01221753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*